Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.

Steinhardt MJ, Hegenbart U, Hellou T, Oubari S, Roussel M, Schwotzer R, Buadi F, Dingli D, Binder M, Kourelis T, Zanwar SS, Rieger MJ, Morbach C, Cejka V, Gerber B, Störk S, Einsele H, Kumar S, Gertz M, Carpinteiro A, Kortum KM, Muchtar E, Dispenzieri A, Schönland S

Open source

DOI: 10.1002/ajh.70371
Published: 2026 Aug
Container: American journal of hematology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ajh.70371,
  title = {Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.},
  author = {Steinhardt MJ and Hegenbart U and Hellou T and Oubari S and Roussel M and Schwotzer R and Buadi F and Dingli D and Binder M and Kourelis T and Zanwar SS and Rieger MJ and Morbach C and Cejka V and Gerber B and Störk S and Einsele H and Kumar S and Gertz M and Carpinteiro A and Kortum KM and Muchtar E and Dispenzieri A and Schönland S},
  year = {2026},
  journal = {American journal of hematology},
  doi = {10.1002/ajh.70371},
  url = {https://doi.org/10.1002/ajh.70371}
}

RIS

TY  - JOUR
TI  - Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.
AU  - Steinhardt MJ
AU  - Hegenbart U
AU  - Hellou T
AU  - Oubari S
AU  - Roussel M
AU  - Schwotzer R
AU  - Buadi F
AU  - Dingli D
AU  - Binder M
AU  - Kourelis T
AU  - Zanwar SS
AU  - Rieger MJ
AU  - Morbach C
AU  - Cejka V
AU  - Gerber B
AU  - Störk S
AU  - Einsele H
AU  - Kumar S
AU  - Gertz M
AU  - Carpinteiro A
AU  - Kortum KM
AU  - Muchtar E
AU  - Dispenzieri A
AU  - Schönland S
PY  - 2026
JO  - American journal of hematology
DO  - 10.1002/ajh.70371
UR  - https://doi.org/10.1002/ajh.70371
ER  -

APA

MJ, S., U, H., T, H., S, O., M, R., R, S., F, B., D, D., M, B., T, K., SS, Z., MJ, R., C, M., V, C., B, G., S, S., H, E., S, K., M, G., A, C., KM, K., E, M., A, D., & S, S. (2026). Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.. American journal of hematology. https://doi.org/10.1002/ajh.70371

Source records

pubmed · retrieved 2026-09-26T22:02:20.634Z